Editors' declarations of interest
Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease – algorithm for practical management
Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis
Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation
Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors
Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong
Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma
Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C
Altered natural killer cells subsets distribution in children with hepatitis C following vertical transmission
Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US – the ENUMERATE study
Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B
Population-based epidemiology of primary biliary cirrhosis in South Korea
Editorial: screening for NAFLD – a promising strategy to mitigate future burden of liver disease
Editorial: what can be done when infliximab stops working in ulcerative colitis?
Editorial: what can be done when infliximab stops working in ulcerative colitis? Authors' reply
Letter: coffee consumption and gallstone disease – a cautionary note on the assignment of exposure values in dose–response meta-analyses
Letter: coffee consumption and gallstone disease – a cautionary note on the assignment of exposure values in dose–response meta-analyses. Authors' reply
Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab
Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab– authors' reply
Letter: factors determining liver fibrosis – more to come
Prostaglandin E1 therapy with alprostadil and risk reduction in early hepatic cellular carcinoma after liver transplantation
Letter: prostaglandin E1 therapy with alprostadil and risk reduction of early hepatic cellular carcinoma after liver transplantation – authors' reply
Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma
Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma – authors' reply
Letter: wide variation in faecal calprotectin values according to the assay
Letter: wide variation in faecal calprotectin values according to the assay – authors' reply
Letter: promising results of Helicobacter pylori eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy